The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
09 2022
Historique:
received: 31 01 2022
revised: 21 06 2022
accepted: 17 08 2022
entrez: 16 3 2023
pubmed: 17 3 2023
medline: 17 3 2023
Statut: epublish

Résumé

The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14 The MDM2 inhibitor Navtemadlin arrests mouse tumor growth and potentiates radiotherapy. Our results support a threshold model for apoptosis induction that requires a high, prolonged p53 signaling for cancer cells to become apoptotic.

Identifiants

pubmed: 36922937
doi: 10.1158/2767-9764.CRC-22-0053
pii: CRC-22-0053
pmc: PMC10010373
doi:

Substances chimiques

Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27
Tumor Suppressor Protein p53 0
Antineoplastic Agents 0
Ubiquitin-Protein Ligases EC 2.3.2.27
MDM2 protein, human EC 2.3.2.27
MDM4 protein, human 0
Proto-Oncogene Proteins 0
Cell Cycle Proteins 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Pagination

1075-1088

Informations de copyright

© 2022 The Authors; Published by the American Association for Cancer Research.

Déclaration de conflit d'intérêts

P. Kannan reports other from Avaant Imaging Inc outside the submitted work. W.W. Kretzschmar reports other from Vanadis Diagnostics, PerkinElmer Inc outside the submitted work. F. Wermeling reports grants from Pfizer outside the submitted work. M. Nestor reports grants from Swedish Cancer Society, Swedish Childhood Cancer Fund, Stiftelsen Ulf Lundahls minnesfond, and Swedish Research Council during the conduct of the study. No disclosures were reported by the other authors.

Références

Mol Cancer Ther. 2008 Apr;7(4):993-9
pubmed: 18413812
Clin Cancer Res. 2021 Oct 1;27(19):5236-5247
pubmed: 34301750
Annu Rev Pathol. 2016 May 23;11:617-44
pubmed: 27022975
Mol Cancer Ther. 2015 Mar;14(3):649-58
pubmed: 25567130
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
ACS Med Chem Lett. 2013 Apr 02;4(5):466-9
pubmed: 24900694
Radiol Oncol. 2010 Mar;44(1):1-12
pubmed: 22933884
Commun Biol. 2021 Jan 4;4(1):6
pubmed: 33398023
Mol Cell. 2016 Jun 16;62(6):890-902
pubmed: 27264869
Clin Cancer Res. 2017 Oct 15;23(20):6044-6053
pubmed: 28659312
Oncogene. 2005 Nov 3;24(48):7224-37
pubmed: 16007132
Pigment Cell Melanoma Res. 2016 May;29(3):266-83
pubmed: 26833684
J Med Chem. 2012 Jun 14;55(11):4936-54
pubmed: 22524527
Cold Spring Harb Perspect Med. 2017 May 1;7(5):
pubmed: 28270530
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
Blood. 2015 May 21;125(21):3273-80
pubmed: 25847014
PLoS One. 2012;7(9):e44328
pubmed: 22957064
BMC Cancer. 2011 Feb 21;11:79
pubmed: 21338495
BMC Cancer. 2010 Jun 22;10:316
pubmed: 20569441
FEBS Lett. 2010 Jul 16;584(14):2981-9
pubmed: 20540941
PLoS One. 2017 Dec 11;12(12):e0189379
pubmed: 29228061
J Med Chem. 2014 Feb 27;57(4):1454-72
pubmed: 24456472
Oncogene. 2004 Mar 25;23(13):2347-56
pubmed: 14743208
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
Nat Methods. 2014 Jan;11(1):59-62
pubmed: 24240322
Mol Cell. 2006 Mar 17;21(6):749-60
pubmed: 16543145
Cancer Res. 2001 Aug 15;61(16):6008-11
pubmed: 11507043
Cell Death Differ. 2013 Apr;20(4):576-88
pubmed: 23306555
J Med Chem. 2013 Jul 25;56(14):5979-83
pubmed: 23808545
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Invest New Drugs. 2020 Jun;38(3):831-843
pubmed: 31359240
Oncogene. 2003 May 19;22(20):3092-8
pubmed: 12789286
Cell Death Discov. 2017 Mar 20;3:17017
pubmed: 28386458
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643228
Elife. 2014 May 27;3:e02200
pubmed: 24867637
Blood Adv. 2019 Jul 9;3(13):1939-1949
pubmed: 31253596
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Mol Cancer Ther. 2015 Sep;14(9):1994-2003
pubmed: 26162687
Am J Cancer Res. 2012;2(5):492-507
pubmed: 22957303
Nature. 2014 Sep 25;513(7519):481-3
pubmed: 25254460
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nat Rev Drug Discov. 2014 Mar;13(3):217-36
pubmed: 24577402
J Mol Cell Biol. 2019 Jul 19;11(7):586-599
pubmed: 31310659

Auteurs

Katrine Ingelshed (K)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Diana Spiegelberg (D)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Pavitra Kannan (P)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Linnéa Påvénius (L)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Jessica Hacheney (J)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Long Jiang (L)

Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Center for Molecular Medicine, Stockholm, Sweden.

Silke Eisinger (S)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Danai Lianoudaki (D)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Dilraj Lama (D)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Francisca Castillo (F)

Center for Molecular Medicine, Stockholm, Sweden.
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

Cecilia Bosdotter (C)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Warren W Kretzschmar (WW)

Vanadis Diagnostics, PerkinElmer Inc, Sollentuna, Sweden.

Omayma Al-Radi (O)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Nicolas Fritz (N)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Eduardo J Villablanca (EJ)

Center for Molecular Medicine, Stockholm, Sweden.
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

Mikael C I Karlsson (MCI)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Fredrik Wermeling (F)

Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Center for Molecular Medicine, Stockholm, Sweden.

Marika Nestor (M)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

David P Lane (DP)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Saikiran K Sedimbi (SK)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH